Navana Pharmaceuticals PLC

DSE:NAVANAPHAR Stock Report

Market Cap: ৳5.3b

Navana Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Navana Pharmaceuticals has been growing earnings at an average annual rate of 22.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 23.4% per year. Navana Pharmaceuticals's return on equity is 9.1%, and it has net margins of 5.7%.

Key information

22.6%

Earnings growth rate

14.8%

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth rate23.4%
Return on equity9.1%
Net Margin5.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Navana Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DSE:NAVANAPHAR Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247,4044202,2360
30 Jun 246,8984052,1360
31 Mar 246,5044392,0940
31 Dec 236,2584362,0000
30 Sep 236,0024021,9380
30 Jun 235,7063571,8410
31 Mar 235,3313311,6480
31 Dec 225,0532941,6490
30 Sep 224,8902851,6100
30 Jun 224,7592741,5910
30 Jun 213,6072021,2650
30 Jun 203,1491371,1350

Quality Earnings: NAVANAPHAR has high quality earnings.

Growing Profit Margin: NAVANAPHAR's current net profit margins (5.7%) are lower than last year (6.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NAVANAPHAR's earnings have grown significantly by 22.6% per year over the past 5 years.

Accelerating Growth: NAVANAPHAR's earnings growth over the past year (4.4%) is below its 5-year average (22.6% per year).

Earnings vs Industry: NAVANAPHAR earnings growth over the past year (4.4%) exceeded the Pharmaceuticals industry -5.5%.


Return on Equity

High ROE: NAVANAPHAR's Return on Equity (9.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:03
End of Day Share Price 2024/12/22 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Navana Pharmaceuticals PLC is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution